Partners Capital Investment Group LLP purchased a new stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 8,833 shares of the biopharmaceutical company’s stock, valued at approximately $1,056,000.
Other institutional investors and hedge funds have also made changes to their positions in the company. Victory Capital Management Inc. grew its stake in Alexion Pharmaceuticals by 8.6% during the third quarter. Victory Capital Management Inc. now owns 121,142 shares of the biopharmaceutical company’s stock worth $16,995,000 after buying an additional 9,639 shares in the last quarter. Andra AP fonden boosted its stake in shares of Alexion Pharmaceuticals by 12.5% in the 3rd quarter. Andra AP fonden now owns 9,000 shares of the biopharmaceutical company’s stock valued at $1,263,000 after purchasing an additional 1,000 shares in the last quarter. Dupont Capital Management Corp bought a new position in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $156,000. BT Investment Management Ltd bought a new position in Alexion Pharmaceuticals in the 3rd quarter valued at approximately $165,000. Finally, Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Alexion Pharmaceuticals by 3.1% in the 3rd quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 33,301 shares of the biopharmaceutical company’s stock valued at $4,672,000 after buying an additional 995 shares during the last quarter. Institutional investors and hedge funds own 95.38% of the company’s stock.
In other news, SVP Heidi L. Wagner sold 655 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Monday, February 5th. The stock was sold at an average price of $117.26, for a total value of $76,805.30. Following the completion of the transaction, the senior vice president now owns 32,635 shares in the company, valued at approximately $3,826,780.10. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at approximately $4,399,600.36. The disclosure for this sale can be found here. Insiders sold 31,253 shares of company stock worth $3,656,229 in the last ninety days. Corporate insiders own 4.35% of the company’s stock.
Several analysts have recently weighed in on ALXN shares. Cowen reiterated a “buy” rating and issued a $163.00 price objective on shares of Alexion Pharmaceuticals in a research note on Friday, March 9th. Raymond James Financial reaffirmed an “outperform” rating and set a $130.00 price objective (down from $178.00) on shares of Alexion Pharmaceuticals in a report on Thursday, January 4th. They noted that the move was a valuation call. UBS Group cut Alexion Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a research note on Thursday, January 4th. Credit Suisse Group reiterated an “outperform” rating and set a $147.00 target price on shares of Alexion Pharmaceuticals in a research note on Thursday, January 18th. Finally, BidaskClub upgraded Alexion Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Wednesday, December 27th. Three research analysts have rated the stock with a sell rating, one has given a hold rating and twenty have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and a consensus target price of $154.64.
Shares of Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) traded up $1.60 during trading hours on Wednesday, reaching $122.68. The company’s stock had a trading volume of 1,305,723 shares, compared to its average volume of 2,080,000. The stock has a market capitalization of $27,200.00, a PE ratio of 56.53, a price-to-earnings-growth ratio of 1.18 and a beta of 1.13. The company has a debt-to-equity ratio of 0.34, a current ratio of 3.10 and a quick ratio of 2.62. Alexion Pharmaceuticals, Inc. has a fifty-two week low of $96.18 and a fifty-two week high of $149.34.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.09 by $0.39. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. The business had revenue of $909.70 million for the quarter, compared to analysts’ expectations of $880.38 million. During the same period last year, the firm posted $1.26 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis. equities analysts forecast that Alexion Pharmaceuticals, Inc. will post 6.12 earnings per share for the current year.
WARNING: “8,833 Shares in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) Acquired by Partners Capital Investment Group LLP” was posted by The Lincolnian Online and is owned by of The Lincolnian Online. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright and trademark law. The correct version of this story can be accessed at https://www.thelincolnianonline.com/2018/03/14/partners-capital-investment-group-llp-buys-new-stake-in-alexion-pharmaceuticals-inc-alxn.html.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.